Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026
Source: SeekingAlpha
2026-04-15 16:07:01 ET
The last time I spoke about Biohaven Ltd. ( BHVN ) it was with a Seeking Alpha article entitled " Biohaven: Despite Troriluzole Program Delay, FDA Review On Track For Q4 2025 ." With respect to this article, I mentioned that the company was approaching its review by the FDA of its drug troriluzole for the treatment of patients with Spinocerebellar Ataxia [SCA]. I had a Strong Buy on this stock the last time around based on this key event....
Read the full article on Seeking Alpha
For further details see:
Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026
Biohaven Ltd.
NASDAQ: BHVN
BHVN Trading
-3.93% G/L:
$10.825 Last:
890,011 Volume:
$11.33 Open:
BHVN Latest News
June 01, 2026 07:30:00 am
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
May 27, 2026 07:30:00 am
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
BHVN Stock Data
$1,610,213,046
113,271,989
1.64%
9
N/A
Biotechnology & Life Sciences
Healthcare
US
New Haven
